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ABSTRAK 
FAKTOR-FAKTOR YANG MEMPENGARUH PEMULIHAN SEL-SEL DARAH 
SELEPAS PEMINDAHAN AUTOLOGOUS PERIFERAL DARAH SEL STEM 
UNTUK PESAKIT LIMFOPROLIFERATIF DI HOSPITAL UNIVERSITI SAINS 
MALAYSIA. 
Pengenalan: Pemindahan Autologous Periferal Darah Sel Stem ( APBSCT ) adalah antara 
pilihan terapi yang boleh digunakan dalam pelbagai penyakit neoplastik hematologi . Di 
Hospital Universiti Sains Malaysia (HUSM ), APBSCT digunakan untuk  multiple 
myeloma  dan limfoma kerana ianya dikaitkan dengan pelbagai kebaikan dan komplikasi 
yang kurang berbanding alogenik pemindahan darah sel stem. 
 
 Objektif: Kajian ini adalah bertujuan untuk mengenal pasti faktor-faktor yang  
mempengaruhi kepantasan pemulihan sel sel darah  pada pesakit penyakit limfoproliferatif 
yang menjalani APBSCT. 
 
Metodologi: Analisis data retrospektif dilakukan kepada semua pesakit  limfoma dan 
multiple myeloma yang dirawat dengan APBSCT di HUSM dari tahun 2010 hingga 2013. 
Kesemua data dikumpulkan melalui pencarian di dalam fail rekod dan juga Informasi 
Hematologi System Pesakit (HPIS) intranet. Dua belas faktor dianalisa untuk menentukan 
faktor apa  yang mempengaruhi kepantasan pemulihan untuk platelet dan neutrofil. Definisi 
pemulihan neutrofil ialah hari pertama dari tiga hari berturut-turut dimana jumlah neutrofil 
melebihi  ≥ 0.5 x 109/L tanpa sokongan transfusi dan definisi untuk platelet ialah hari 
xi 
 
pertama dari tujuh hari berturut-turut dimana jumlah platelet melebihi ≥ 20 x 109/L dimana 
tiada transfusi platelet diberi. Kepantasan pemulihan untuk platelet dan neutrofil 
didefinasikan sebagai sama atau kurang dari 14 hari dari hari transfusi darah sel stem. Data 
dianalisa dengan menggunakan Pearson Chi Square/Fisher’s Exact test dan kemudian, 
faktor-faktor yang signifikan dianalisa dengan menggunakan Multiple Logistic Regression 
test. Ujian statistik dengan nilai p < 0.05 adalah menunjukkan statistik yang signifikan. 
 
Hasil Kajian: Daripada 40 pesakit, keputusan kajian menunjukkan bahawa 95% pesakit 
telah mencapai pemulihan neutrofil yang berjaya dan 82.5% pesakit mempunyai pemulihan 
platlet yang berjaya. Dari dua kumpulan yang berjaya mencapai pemulihan ini, faktor 
utama yang mempengaruhi  kecepatan pemulihan untuk neutrofil  adalah jumlah bilangan 
stem sel (CD34+) dan faktor-faktor yang mempengaruhi kecepatan pemulihan platlet  
adalah jumlah bilangan stem sel (CD34+) dan tahap penyakit tersebut pada masa diagnosis. 
 
Kesimpulan: Mengenal pasti faktor-faktor yang boleh memberi manfaat kepada pesakit 
yang menjalani pemindahan sel stem adalah penting dan hasil kajian yang diperoleh dapat 
digunakan sebagai panduan kepada pakar perubatan klinikal untuk mengoptimumkan 
pengurusan rawatan pesakit mereka. 
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ABSTRACT 
FACTORS INFLUENCING ENGRAFTMENT IN AUTOLOGOUS PERIPHERAL 
BLOOD STEM CELL TRANSPLANTATION FOR LYMPHOPROLIFERATIVE 
DISEASE PATIENTS IN HOSPITAL UNVERSITI SAINS MALAYSIA. 
Introduction: Autologous peripheral blood stem cells transplantation (APBSCT) is a 
therapeutic option which can be used in various haematological neoplastic disorders. In 
Hospital Universiti Sains Malaysia (HUSM), APBSCT is practiced in multiple myeloma 
and lymphoma cases as it is associated with substantial advantages and fewer 
complications compared to allogenic stem cell transplantation. 
 Objectives: The aim of this study was to identify factors associated with rapid 
haematopoietic engraftment in lymphoproliferative disease patients undergoing APBSCT. 
Methodology: A retrospective data analysis was done on lymphoma and multiple myeloma 
patients treated with APBSCT at HUSM from 2010 until 2013.Data was collected from the 
record file Haematology Patient Information System (HPIS) in the institution  intranet. 
Twelve factors were analyzed to determine the engraftment time for platelet and neutrophil. 
Engraftment of neutrophils is defined as count at least 0.5 x 109/L for three consecutive 
days and platelet count at least 20 x 109/L for seven consecutive days without transfusion 
support. Early engraftment for both neutrophils and platelet were defined as less than 14 
days from the day of stem cell infusion. Data were analyzed using Pearson Chi Square/ 
Fisher’s Exact and significant factors were analysed with Multiple Logistic Regression test 
with p < 0.05 indicates statistically significance.  
xiii 
 
Results: Forty patients had been studied, the results showed that 95% patients had 
successful neutrophil engraftment and 82.5% patients had successful platelet engraftment. 
From these success groups, the main predictive factor for rapid engraftment for neutrophil 
is stem cell (CD34+) count while predictive factors that influenced rapid platelet 
engraftment were (CD34+) count and the stage of the disease at diagnosis. 
 
Conclusion: In conclusion, identifying factors that may benefit patients undergoing stem 
cell transplantation are important and the results obtained can be useful as a guidance to 
clinical haematologists to optimize their management. 
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CHAPTER 1  
________________________
INTRODUCTION 
 
 
 
 
 
1.0 GENERAL INTRODUCTION 
 
A stem cell transplantation is a specialized procedure where it is done with the aim of 
eliminating the cancer cells with high dose chemotherapy. After completing the treatment, 
stem cells that were collected earlier were re-infused into the patients and homing of the 
stem cells will then occur naturally. The stem cells infused can overcome the toxicities that 
are caused by the myeloablative dose of chemotherapy or radiotherapy given. The main 
purpose of bone marrow stem cell transplantation is to provide cure of the disease. 
 
The source of stem cells can be acquired through bone marrow aspirate, peripheral blood or 
from the cord blood. However nowadays, stem cells taken from the peripheral blood is the 
first choice since it is not that invasive compared to bone marrow aspirate and the enough 
amount of stem cells can be collected compared with stem cells collected from the cord 
blood where usually it has low number of enough stem cells. 
 
There are three types of  stem cell transplantation namely allogeneic transplant, autologous 
transplant and syngeneic transplant. In allogeneic transplant, it involves harvesting stem 
cells from a genetically similar donor or another name of it is  Human Leucocytes Antigen 
(HLA) matched donor. HLA matched can be from related donor (found within family 
members) or from unrelated donor. The autologous transplant involves harvesting stem 
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cells from the patient itself and this stem cells will be infused back into the donor’s blood 
for homing into the bone marrow. The syngeneic transplant involves using graft or stem 
cells from an identical twin. 
 
Many diseases now can be cured by doing bone marrow stem cell transplantation. Example 
of diseases that are proven to be effective with autologous stem cell transplantation can be 
divided into malignant and non-malignant diseases. For malignant diseases, examples are 
non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, acute myeloid 
leukaemia, neuroblastoma and etc. and for non malignant diseases, examples are 
amyloidosis and autoimmune diseases (Collagen disease).  In Hospital Universiti Sains 
Malaysia (HUSM), there are two main diseases treated with autologous peripheral blood 
stem cell transplantation (APBSCT) namely the lymphoma (includes Hodgkin and non-
Hodgkin) and multiple myeloma. Both are members of a big group of diseases called 
lymphoproliferative disease.  
 
Previous, when planning for autologous Haematopoietic Stem Cell Transplantation 
(HSCT), sources of the stem cells were taken from the bone marrow but currently, most 
institutions have moved to autologous peripheral HSCT as it gives less stress to the patient 
where patient do not require general anaesthesia which is used in bone marrow 
transplantation procedure. Besides, in  autologous peripheral HSCT it is associated with 
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advantages such as faster haematological engraftment and the treatment related cost is low 
compared to bone marrow transplantation (Hartmann et al., 1997). 
 
So far  in HUSM, no study has been conducted to see the successful of  engraftment in our 
lymphoproliferative patients (multiple myeloma and lymphoma). By conducting this study, 
it is hope that results that are obtained may be useful as a guidance to the clinical 
haematologist to predict and choose which patient that may benefit from undergoing stem 
cell transplantation and optimize their individual management. Besides, this study may 
indirectly assess the quality of our stem cell mobilizing procedure and processing in the 
Stem Cell Transplantation Laboratory Unit, HUSM. 
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CHAPTER 2 
________________________ 
    LITERATURE REVIEW 
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2.0 LITERATURE REVIEW 
2.1 OVERVIEW OF STEM CELL TRANSPLANTATION IN MALAYSIA 
 
The first bone marrow transplant conducted in Malaysia was in 1987. Since then, the 
number has been increased steadily over the years. The latest data that are available from 
the National Transplant Registry showed that from 1987 until 2011, the total number up to 
the date were 2260 patients. These procedures were done in ten transplant centres which 
were available in Malaysia; three of which were university based, three were government 
based and the remaining four were private hospitals. From these ten centres, three are 
specialized in paediatric transplantation and others are for adult transplantation which most 
of them conducting allogeniec transplantation. Hospital Ampang has the highest number of 
procedures among all. This is probably because it is the main tertiary referral centre in the 
country. Table 2.1 shows the list of transplant centres in Malaysia. 
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Table 2.1: Transplant centres  in Malaysia (Adapted from National Transplant 
Registry, 2011) 
Transplant Centre Category Name of Transplant Centre 
University based 1. Hospital Universiti Kebangsaan Malaysia 
2. Hospital Universiti Sains Malaysia 
3. University of Malaya Medical Centre (Adult) 
4. University of Malaya Medical Centre (Pediatric) 
Government based 1. Hospital Kuala Lumpur, (Adult) 
2. Hospital Kuala Lumpur, Institute Pediatrics 
(Pediatric) 
3. Hospital Ampang 
4. Hospital Pulau Pinang 
Private based 1. Sime Darby Medical Centre, Subang Jaya (Adult) 
2. Sime Darby Medical Centre, Subang Jaya 
(Pediatric) 
3. Gleneagles Medical Centre, Penang 
4. Lam Wah Ee Hospital, Penang 
5. Ampang Puteri Specialist Hospital 
 
Many diseases can be treated with stem cell transplantation. Diseases that are being treated 
with stem cell transplantation in Malaysia can be categorized into malignant and non- 
malignant. Table 2.2 shows the list of the diseases. 
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Table 2.2: Diseases treated with stem cell transplantation in Malaysia (Source from 
national Transplantation Registry 2011). 
Malignant Non- malignant 
 
Acute leukaemia 
• Acute leukaemia, unclassified 
• Acute undifferentiated leukaemia 
• Acute Lymphocytic Leukaemia (ALL) 
• Acute Myelogenous Leukaemia 
(AML) denovo 
• AML post-chemotherapy 
• AML post-MDS 
Hypoplasticanaemia 
• Aplastic anaemia 
• Fanconi anaemia 
Chronic leukaemia 
• Chronic lymphocytic leukaemia 
• Chronic myeloid leukaemia 
Erythrocytic Disorders 
• Diamond-Blackfan anaemia   
• Congenital Dyserythropoeitic Anaemia 
(CDA) 
 
Lymphoma 
• Hodgkin lymphoma 
• Non-Hodgkin lymphoma, Aggressive  
• Non-Hodgkin lymphoma, Indolent 
Haemoglobinopathy 
• Thalassaemia major  
• Sickle Cell Anaemia 
Solid tumors 
• Carcinoma, breast 
• Carcinoma, ovary 
• Germ Cell Tumour (GCT)-testicular 
• GCT-primary non-testis 
• Ewing sarcoma 
• Glioma 
• Hepatoblastoma 
• Neuroblastoma 
• Rhabdomyosarcoma 
• Soft tissue sarcoma (non-RMS) 
• Wilms tumour 
• Primitive NeuroectodermalTumour 
(NET) 
Others 
• Haemophagocytic Lymphohistiocytosis 
Syndrome 
• Congenital Immunodeficiencies Others 
• Osteopetrosis 
 
Myelodysplasia 
• Juvenile Myelomonocytic Leukaemia 
• Myelodyplastic syndrome (MDS)  
• Myelofibrosis 
 
 
Multiple Myeloma  
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Overall, from 1987 until 2011, there was a slight male preponderance with 56% male 
patients and 44% female patients. Chinese is the largest ethnic group that were involved in 
transplantation (43%) followed by the Malays (40%) and the Indians (8%). The youngest 
age undergone for transplantation was at one month and the oldest age was at 72 years old 
in this country. Looking at the age category, 47% patient’s age below 19 years old were 
transplanted. Fifty-one percent patients were transplanted in the age group of 20-59 years 
and patients older than 60 years old constitute the minority group with only 2%. 
 
The two most popular type of transplantation performed were allogeneic and syngeneic 
transplantation with 61 % and the rest was autologous. Most of allogeneic transplantation 
was done on malignant diseases and majority falls under haematological malignancy. For 
example, acute leukaemia remains the top disease for transplantation with 37% followed 
with lymphomas (23%) and chronic myeloid leukaemia (9%). For non-malignant diseases, 
haemoglobinopathies constitute about 8% of cases. The percentage of chronic myeloid 
leukaemia planned for allogeneic transplantation were not that high compared to other 
malignant haematological disease perhaps due to the advances in the used of novel drugs 
such as the  first generation tyrosine kinase inhibitor (Imatinib) or second generation 
(Nalotinib).  
 
 The sources of stem cell transplant were harvested mostly from peripheral (70%). Bone 
marrow source is used in 26% of cases and cord blood is the less popular with 4% of cases. 
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The top three causes of death in transplanted patients were the underlying illness itself 
(59%), sepsis (17%) and graft versus host disease (8%). Other less common causes include 
haemorrhage, veno-occlusive disease, organ failure,  interstitial pneumonitis and the 
remaining 5% of cases were unknown. 
 
The current problem is not every patient can afford for stem cell transplantation. The cost 
for allogeniec transplantation is quite high compared to autologous transplantation. Only 
three government hospitals provide transplant services on subsidized basis and the 
procedure depends on limited financial budget. Unlike in the university hospital, there are 
social welfare and non government organizations that will help in finding financial 
resources in order to help patients in need. 
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2.2 HAEMATOPOIETIC STEM CELL TRANSPLANTATION 
2.2.1 Haematopoietic Stem Cell 
Haematopoietic stem cells are cells that are capable to differentiate into red cells, white 
cells (neutrophil, monocyte, lymphocyte, basophil and eosinophil) and platelet. They have 
the ability of self renewal and they are located in the bone marrow in a small number. They 
can be identified by immunoflowcytometry  where they are positive for CD34+. Figure 2.1 
shows schematic cartoon on how stem cells are able to differentiate into various cell 
lineages. 
 
Figure 2.1: Diagrammatic presentation of the capability of the bone marrow 
pluripotent stem cell to differentiate into different cell lineages (Source: Essential 
Haematology, 6th edition, 2011) 
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2.2.2 Types of Haematopoietic Stem Cell Transplantation 
 
Before transplantation, patient is given chemotherapy , radiotherapy  or both in 
combination to destroy remaining malignant cells in the body including in the bone 
marrow. During this process (myoablative), all the healthy cells in the marrow are also 
destroyed and this will allow a new place for the transfused stem cells to grow or engraft 
later. In general, there are  three types  of transplantation namely autologous, allogeniec and 
cord haematopoietic blood stem cell transplantation (Hoffbrand et al., 2010). 
 
2.2.3 Autologous Haematopoietic Stem Cell Transplantation 
The meaning of the term auto is self. It is a type of transplant that utilizes stem cells that is 
collected earlier from the patient himself or herself before they are given high dose 
chemotherapy or radiotherapy treatment. The stem cells are stored in a nitrogen liquid 
container and this is known as cryopreservation. After completing the myoablative regime, 
the stem cells collected earlier is transfused back into the patient’s blood. Homing of stem 
cells will take place in the bone marrow to generate new population of haematopoietic 
cells. Figure 2.2 shows the overview process of autologous HSCT. Diseases for which 
autologous HSCT may be indicated are listed in Table 2.3. 
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 Figure 2.2: Autologous HSCT process (Source from Georgia Regents University 
Transplant Centre 2014). 
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Table 2.3: Diseases for which autologous HSCT may be indicated (Source: Approach 
to Haematopoietic Stem Cell Transplantation, Akiyoshi Takami, Sysmex Corporation 
2010). 
Malignant diseases Nonmalignant diseases 
Multiple myeloma Autoimmune disease (Collagen disease) 
Non-Hodgkin lymphoma Amyloidosis 
Hodgkin lymphoma  
Acute myeloid leukemia  
Neuroblastoma  
Rhabdomyosarcoma  
Brain tumors (medulloblastoma, 
ependymoma, peripheral neuroectodermal 
tumor, etc)  
 
Hepatoblastoma  
Wilms tumor  
Ewing sarcoma  
Osteosarcoma  
Germ cell tumor  
Breast cancer  
Ovarian cancer  
Lung cancer  
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2.2.4 Allogeneic Haematopoietic Stem Cell Transplantation 
The meaning of the term allo is other. Here, the stem cells are harvested from another 
person called a donor. To achieve a successful allogeneic HSCT, it is very important to use 
blood from a donor who has the best matching of HLA antigen and if preferable best match 
of HLA genotype with the recipient. This can be attained by screening close family 
members. The most likely good match can be found from patient’s brother or sister. In 
some circumstances, a good match also can be found in parents, children and other 
relatives. However, sometimes it is difficult to get it from the family members but there is 
another alternative option where transplantation can be done from a donor who is not 
related with the patient. Such transplant is known as match unrelated donor (MUD) where 
there is some mismatch in HLA between the donor and the recipient. The search of MUD 
can be applied from national bone marrow registries. But in this case, certain risk or 
complication is higher such as patient is prone to get severe GVHD, graft failure and 
others. Diseases for which allogeneic HSCT may be indicated are listed in Table 2.4. 
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Table 2.4: Diseases for which allogeneic HSCT may be indicated (Source: Approach 
to Haematopoietic Stem Cell Transplantation, Akiyoshi Takami, Sysmex Corporation 
2010). 
Malignant diseases Nonmalignant diseases 
Acute myeloid leukaemia Aplastic anaemia 
Acute lymphocytic leukaemia Paroxysmal nocturnal haemoglobinuria 
non-Hodgkin lymphoma Severe combined immunodeficiency 
Myelodysplastic syndrome Fanconi anaemia 
Multiple myeloma Diamond-Blackfan anaemia 
Chronic myeloid leukaemia Sickle cell disease 
Chronic lymphocytic leukaemia Wiskott-Aldrich syndrome 
Renal cell carcinoma Osteopetrosis 
Pancreatic carcinoma Congenital metabolic disease 
Large intestine carcinoma Autoimmune disease 
Breast cancer  
 
2.2.5 Umbilical Cord Blood Transplantation 
This is also one of allogeneic type of transplant. Cord blood is a type of blood taken from 
the umbilical cord and placenta which connect the mother and the baby. Haematopoietic 
stem cells is harvested from it and stored or cryopreserved until they are needed for 
transplant. There are many advantages of cord blood transplantation. First, stem cells in the 
cord blood are very immature, therefore there is a less need for perfect matching or in other 
words HLA mismatched to some degree can be done for transplantation. Secondly, since 
the stem cells are taken from baby’s cord blood, there is no stress and no risk to the donors. 
16 
 
Thirdly, as the cord blood is readily available, the transplantation can be performed 
relatively fast and finally, cases of GVHD are rare compared with other stem cell sources. 
However, it also comes with drawback such as it has slow engraftment rate for WBC, RBC 
and platelet after transplantation and making patients at disadvantage where infection can 
occur easily and cause prolonged hospitalization. Besides, since the stem cells are in small 
quantities, cases of graft failure are frequent and also additional cord blood from the same 
donor cannot be obtained (Schoemans et al., 2006). 
 
2.3 AUTOLOGOUS PERIPHERAL HAEMATOPOIETIC STEM CELL 
TRANSPLANTATION 
As we already know, the sources of stem cells can be harvested from bone marrow, 
peripheral blood and cord blood. Among the three, stem cells collected from the peripheral 
blood is the most commonly used in stem cell transplant procedure for a number of diseases 
including non malignant and malignant (Passweg et al., 2013). In Malaysia, the scenario 
follows the same trend as in the European country practices and this is reflected in the data 
from National Transplant Registry 2011. 
 
There are many benefits of autologous PSCT, one of them is it takes fewer days for the 
engraftment of hematopoietic cells to occur. For example, in PBSCT for allogeneic 
transplantation the median day for engraftment is 12 days compared to bone marrow which 
took about 17 days (Bensinger et al., 2001). 
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Besides, unlike in allogeneic HSCT, patients undergone autologous PBST are not prone to 
get GVHD. The treatment related mortality rate is also low compared to allogeneic HSCT. 
For example in lymphoma particularly Hodgkin lymphoma who undergone allogeneic 
HSCT, the treatment related mortality is 51.7% at 4 years (Peniket et al., 2002). 
 
However,  there are still back draws or disadvantages of autologous PBST such as it is 
associated with high relapse rate (Peniket et al., 2002). The postulation cause of this can be 
related to the procedure itself. Since in autologous transplantation, patient’s own blood is 
used, immunosuppressive therapy after the transplant is not required. Therefore, there is a 
chance or probability that some malignant cells may intermixed with the transplant material 
during the process of stem cell harvest. 
 
 
2.4 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN 
MULTIPLE MYELOMA 
 
2.4.1 An Introduction to Multiple Myeloma 
Multiple myeloma is a cancer of plasma cells. Majority of cases are more than 40 years old 
and peak incidence is in the seventh decade of life. The aetiology of multiple myeloma 
remains unknown. But what have been known so far, it is more common in black individual 
(Hoffbrand and Moss, 2011). Besides total accumulation of complex genetic changes, 
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dysregulation of cyclin D is said to be the early unifying event towards its pathogenesis 
(Chesi and Bergsagel, 2013). 
 
Patients can present with symptoms of bone marrow failure that will result in anaemia 
(lethargy, pallor, weakness and tachycardia), leucopenia (frequent infections) and 
thrombocytopenia (easy bleeding). Besides symptoms of kidney failures (swollen legs, 
poor urine output) and bone pain as a result of increased osteoclast activity can be seen. 
 
According to the WHO 2008 criteria, diagnosis of symptomatic multiple myeloma can be 
made when it fulfill three criteria namely the demonstration of monoclonal protein in serum 
or urine, increased clonal plasma cells in the bone marrow and presence of related organ or 
tissue impairment (hypercalcemia, renal insufficiency, anaemia and bone lesions). The 
International Staging System (Table 2.4) is the current standard used in staging multiple 
myeloma (Greipp et al., 2005). Stage III is considered and advanced stage with high tumor 
burden. 
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Table 2.4: International Staging System ( Source: Oxford Handbook of Clinical 
Haematology, 3rd edition, 2009 ) 
Stage of multiple myeloma Level of biochemical markers 
Stage I Serum ß2-Microglobulin <3.5mg/L and 
serum albumin ≥35g/L 
Stage II Serum ß2-Microglobulin <3.5mg/L and 
serum albumin <35g/L 
Or 
Serum ß2-Microglobulin 3.5 - <5.5mg/L 
Stage III Serum ß2-Microglobulin ≥5.5mg/L 
 
 
For assessment of response treatment in multiple myeloma, there are 2 systems can be used 
namely the European Group for Blood and Marrow Transplant (BladÉ et al., 1998) or the 
International Myeloma Working Group (Durie et al., 2006). 
According to the International Myeloma Working Group, there are overall eight response 
subcategory namely stringent complete response (sCR), complete response (CR), very good 
partial response (VGPR), partial response (PR), stable disease (SD), progressive disease, 
clinical relapse and relapse from CR. In HUSM, generally the aim of treatment is at least 
patients achieve VGPR before proceed with transplantation. Criteria for VGPR is when 
patients have serum and urine M-protein detectable by immunofixation but not on 
electrophoresis or ≥90% reduction in serum M-protein/ urine M-protein level <200mg/24 
hour. 
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 2.4.2 Treatment and Role of Autologous HSCT in Multiple Myeloma 
The latest data from National Registry Transplantation showed that from 1987 until 2011, 
multiple myeloma sit at the second place among malignant haematological disorders for 
indication of autologous stem cell transplantation with a total of 6% cases. Multiple 
myeloma is considered incurable disease because most of the patients had disease 
progression and relapse after treatment. In addition, even patients who are considered 
minimal residual disease (MRD) negative, evidence of residual disease can still be detected. 
Currently, younger patients who are newly diagnosed with multiple myeloma, autologous 
stem cell transplantation is considered the gold standard as part of the initial treatment  
(Hübel et al., 2014). 
 
The long term and overall survival of multiple myeloma has dramatically improved 
nowadays with the invention of novel drugs such as thalidomide, bortezomib and 
lenalidomide  together with autologous stem cell transplantation (Palumbo et al., 2011). 
Once patient is diagnosed to have multiple myeloma, the suitability of treatment plan is 
dependent on the age of the patient, co morbidity (including renal, cardiac, hepatic, 
neurologic and pulmonary function), performance status and disease progression status at 
diagnosis. This then can be divided into transplant eligible and non-transplant eligible. 
 In Malaysia, generally patient who age below 60 years old with a reasonable health status 
are selected for autologous stem cell transplantation. However, some European countries 
had experienced of successful treatment in the older patients. In their study, they have 
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concluded that selected patient who is age above 70 years old should not be excluded from 
autologous stem cell transplantation as the toxicity and the outcome seems to be 
comparable with the younger age that is below 65 years old (Gertz and Dingli, 2014). There 
was another study done that reported the same findings (Kumar et al., 2008). The option of 
choosing patient age less 60 years old in Malaysia is perhaps that Asian people are more 
fragile compared to the European where biological and genetic factors may play a role. 
 
In the past, the selected eligible patients are initially given induction chemotherapy which 
could be VAD (which consist of Vincristine, Adriamycin and dexamethasone) or ABCM 
(which consist of Adriamycin, BCNU, Cyclophosphemide, Melphalan). However with the 
availability of new novel agents (Bortezomib, Thalidomide or Lenalinomide), VAD regime 
is no longer being used as these new drugs has shown to be superior. In HUSM, VTD 
regime (which consists of bortezomib, thalidomide and dexamethasone) is selected. The 
aim is to clear the marrow from malignant myeloma cells. After four to six cycles of 
chemotherapy, stem cells collection from the peripheral blood is then collected. There is a 
convincing study which showed that patients who undergone autologous transplantation 
had longer survival time or survival advantages. Their five year survival rate improves to 
52% compared to only 12% for those who treated with just conventional chemotherapy 
(Attal et al., 1996). 
Achievement of a very good partial response (VGPR) and complete remission (CR) post 
autologous stem cell transplantation can be used as one of the predictors for long term 
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clinical outcome (Harousseau et al., 2009; Chanan-Khan and Giralt, 2010). Usually after 
autologous stem cell transplantation procedure completed, patients are given treatment with 
a drug called interferon as a maintenance therapy in the past. However latest data in a 
recent study in 2012 suggest that the combination used of new drugs such as bortezomib , 
dexamethasone and thalidomide (VDT) has shown encouraging result  where it can 
improved remission status of the patient from a very good partial response (VGPR) to 
complete remission (CR) (Cavo et al., 2012). 
 
 For the role of autologous stem cell transplantation in relapse multiple myeloma, some 
studies shows that it is an effective treatment that is well tolerated by patients. Besides it 
also demonstrated an overall good response rate. For an instance in one study done in Italy, 
they have shown that 69% of their patients who undergone a second autologous stem cell 
transplantation after relapse or disease progression following first-line  autologous stem cell 
transplantation showed major response ( ≥ partial response) (Elice et al., 2006). Besides 
other factor that influenced overall survival and progression-free survival includes patients 
who received fewer regimes of chemotherapy before transplantation and also patients who 
had late disease relapse (Cook et al., 2011; Jimenez-Zepeda et al., 2012). 
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2.5 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN 
LYMPHOMA 
 
2.5.1 An Introduction to Lymphoma 
Lymphoma is a group of lymphoid cancers that start in the lymphatic system where 
malignant lymphocytes accumulate. It is the most treatable form of malignancy. It can be 
divided into two major divisions namely Hodgkin lymphoma (HL) and non-Hodgkin 
lymphoma (NHL) and this is based on the presence or absence of Reed-Sternberg (RS) 
cells. 
 
The causes are unknown exactly. However in HL, Epstein-Barr virus (EBV) has been 
postulated to be linked with it as the EBV genome is detected in Hodgkin tissue biopsy 
(Hoffbrand and Moss, 2011). Besides EBV is also linked to a rare type of NHL that is the 
Burkitt lymphoma. There are several known risk factors for NHL which includes 
microbiological infection, previous exposure to radiation, immunodeficiency state due to 
infection ( such as Human Immunodeficiency Virus) or due to prolonged drug treatment. 
 
Patients may present with enlarged lymph nodes at the neck, armpits or groin which are 
painless. The nodes can grow in size and not responsive to antibiotic. Some patients have 
constitutional symptoms such as weight loss and fever. 
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